CClinicalTrials.gg
Sign In
CompletedNCT00606424HX4Updated Feb 2, 2009

An Exploratory, Open Label, Single Center Study of [F-18]HX4

An Early Phase 1 interventional study of 20 mCi dose for a 50 kg individual of [F-18]HX4 in Head and Neck Cancer, sponsored by Siemens Molecular Imaging. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-02-02.

Sponsored by Siemens Molecular Imaging · Early Phase 1 and Interventional

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

[F-18]HX4 is being developed as a diagnostic radiopharmaceutical for PET imaging. This trial is looking at the safety of [F-18]HX4.

The Sponsor is seeking to determine if [F-18]HX4 may serve as a clinically useful hypoxia marker in diagnostic imaging, allowing the rational application of hypoxia related therapies to those patients most likely to benefit from them.

Tumor hypoxia, a situation where tumor cells have been deprived of oxygen, caused cancer cells to become more resistant to the effects of radiotherapy and chemotherapy.

A non-invasive study characterizing tumor hypoxia would facilitate the development of targeted therapies.

The population to be studied consists of a total of ten (10) adult subjects, including, four normal volunteers and six cancer subjects, the latter with a confirmed diagnosis of head and neck cancer, as defined by the protocol eligibility criteria.

The objectives of this exploratory study are to:

  • Gain information on bio-distribution of [F-18]HX4, and to evaluate the PET images of [F-18]HX4 for resolution, signal to background ratio for both intermediate levels of oxygenation, and at extreme levels hypoxia
  • Use this eIND in order to obtain the necessary information to file an IND application with the FDA. The information collected under this exploratory study will not be used for diagnostic purposes, to assess the subject's response to therapy, or for clinical management of the subject.
  • Begin collection of baseline imaging data
  • Collect [F-18]HX4 metabolism data
  • Gain information to improve study design and the conduct of future trials

This investigation will be conducted as an exploratory, open-label, non-randomized, uncontrolled, single center, safety study.

The trial is expected to begin subject enrollment in early January 2008 and end subject participation in June 2008.

The duration of an individual subject's participation includes a screening visit, followed by participation in the actual study starting with the day of dosing with imaging sessions lasting several hours, concluding with a next day safety follow-up visit.

Individual doses of [F-18]HX4 shall not exceed 20 mCi. The IP will be administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose. After IP administration several PET imaging series will be acquired. Also, in order to assess major organ function and electrolyte levels, a metabolites analysis will be performed for this study from predose to 90 minutes postdose.

In order to determine the quantity of [F-18]HX4 and labeled metabolites excreted by the kidney,urine will be collected and pooled at the designated intervals after administration of the investigational product. This excretion data will provide supportive information for calculating human dosimetry estimates from PET imaging biodistribution data collected in human subjects.

For cancer subjects, a tissue biopsy will have been taken or be scheduled to be performed. The biopsy sample will be examined for hypoxic biomarker(s) using immunohistochemistry methods.

02

Conditions studied

  • Head and Neck Cancer

Keywords

  • head and neck cancer
03

In context

Head and Neck Neoplasms

2,344 studies on the registry are indexed under Head and Neck Neoplasms; 551 are open to participants now.

This study's planned enrollment of 10 is below the median of 47 across 1,751 interventional studies indexed under Head and Neck Neoplasms.

Browse Head and Neck Neoplasms studies →

Lead sponsor

Siemens Molecular Imaging is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Normal Volunteers

  • Subject may be male or female and of any race / ethnicity
  • Subject is > 18 years old at the time of investigational product administration
  • Subject or subject's legally acceptable representative provides written informed consent
  • Subject is capable of complying with study procedures
  • Subject is capable of communicating with study personnel

Cancer Subjects

  • Subject may be male or female and of any race / ethnicity
  • Subject is > 18 years old at the time of investigational product administration
  • Subject or subject's legally acceptable representative provides written informed consent
  • Subject is capable of complying with study procedures
  • Subject is capable of communicating with study personnel
  • Subject must have histologically confirmed stage III, or IV squamous cell carcinoma of the head and neck whose primary origin was from the oral cavity, oropharynx, hypopharynx, or larynx. Carcinoma must be staged using the American Joint Committee on Cancer (AJCC) staging criteria version 6. Adequate tumor must be amenable to biopsy via outpatient methods
  • According to the Karnofsky Performance Status Scale, the subject has a value of ≥ 60% at time of screening
  • Subject is scheduled for a clinical FDG PET scan either within 48 hours prior to (with no intervention in between the two scans), or within 48 hours after the investigational [F-18]HX4 PET scan

  • Subject must have normal organ and renal function as defined:

    • total bilirubin within normal institutional limits
    • AST(SGOT)/ALT(SGPT) less than or equal to 2.5 x institutional upper limit of normal
    • creatinine within normal institutional limits
    • BUN within normal institutional limits

Exclusion criteria

Exclusion Criteria:

Normal Volunteers

  • Subject is younger than 18 years old at the time of investigational product administration
  • Female subject is pregnant or nursing--Serum pregnancy test must be negative; test must be completed within 24 hours of dosing or female subject must be either surgically sterilized or post- menopausal, defined as at least one year without menses as reported by the subject
  • Subject is unable to remain still for duration of imaging procedure (\~40 mins)
  • Subject has previously received [F-18]HX4 at any time, or has been involved in an investigative, radioactive research procedure within the past year
  • Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
  • Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives.

Cancer Subjects

  • Subject is younger than 18 years old at the time of investigational product administration
  • Female subject is pregnant or has a positive serum pregnancy test
  • Subject is unable to remain still for duration of imaging procedure
  • Subject has a history of significant renal disease
  • Subject has previously received [F-18]HX4 at any time, or any other investigational product in the past thirty days.
  • Subject has been involved in an investigative, radioactive research procedure within the past year
  • Inadequate tumor sites or volume to allow for biopsy
  • Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete and good quality data
  • Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives
05

Study design

Phase
Early Phase 1
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Interventions

  • Drug20 mCi dose for a 50 kg individual of [F-18]HX4

    All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).

06

What researchers measure

Primary outcomes

  1. Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.

    Time frame: 24 hours

07

Study locations

1 site
  • Michael Yu, MD
    Philadelphia, Pennsylvania 19111, United States
08

References and documents

Publications

  • Doss M, Zhang JJ, Belanger MJ, Stubbs JB, Hostetler ED, Alpaugh K, Kolb HC, Yu JQ. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun. 2010 Dec;31(12):1016-24. doi: 10.1097/MNM.0b013e3283407950. PubMed 20948452 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00606424
Lead sponsor
Siemens Molecular Imaging
First posted
Feb 4, 2008
Start date
Jan 2008
Primary completion
Jan 2009
Completion
Jan 2009
Last update
Feb 2, 2009

Study contacts

Michael Yu, MD
principal investigator · Fox Chase Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Head and Neck Neoplasms→

Other studies from this sponsor

Siemens Molecular Imaging

Start the discussion